Can I Take Melatonin with Leqvio (Inclisiran)?

How Inclisiran (Leqvio) Works in the Body

Inclisiran is a small interfering RNA (siRNA) molecule that silences PCSK9 messenger RNA inside liver cells. After a subcutaneous injection, it is taken up by hepatocytes via GalNAc-receptor-mediated endocytosis, where it reduces PCSK9 protein synthesis. Less circulating PCSK9 means more LDL receptors remain on hepatocyte surfaces, which pulls LDL-C out of the bloodstream.

Key Pharmacokinetic Properties

The drug reaches peak plasma concentration within 4 hours of injection and then distributes rapidly into the liver. Plasma half-life is roughly 9 hours, but the intracellular silencing effect persists for up to 6 months, which is why dosing intervals are so long. Renal excretion handles most of the eliminated drug. Inclisiran is not metabolized by cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4) and does not inhibit or induce any of them. The FDA prescribing information for inclisiran confirms this profile explicitly. [1]

Why CYP450 Status Matters for Interactions

Most drug-supplement interactions occur because two substances compete for the same metabolic enzyme. Statins (especially simvastatin) are classic CYP3A4 substrates, which is why grapefruit juice raises their plasma levels. Inclisiran bypasses that entire system. There is no enzymatic competition pathway through which melatonin can raise, lower, or prolong inclisiran exposure.

Protein Binding Considerations

Inclisiran binds to plasma proteins at greater than 87%. Melatonin also has some protein binding (roughly 60%). Displacement interactions between two highly protein-bound drugs can, in theory, raise free-drug concentrations of either agent. In practice, displacement interactions of clinical significance require both drugs to share the same binding sites at overlapping high concentrations. Given that inclisiran is present in plasma only transiently (a few hours after each injection, administered twice yearly), and melatonin is taken nightly in microgram-to-low-milligram doses, simultaneous high plasma concentrations are virtually impossible under any real-world dosing scenario. [2]

What Melatonin Does Pharmacologically

Melatonin is an endogenous hormone produced by the pineal gland in response to darkness. Exogenous melatonin (0.5 to 10 mg, taken orally) binds MT1 and MT2 receptors in the suprachiasmatic nucleus to advance or consolidate circadian sleep onset. It is also an antioxidant and free-radical scavenger at higher concentrations.

Metabolism and Clearance

Oral melatonin is rapidly absorbed, reaches peak serum levels within 30 to 60 minutes, and is metabolized primarily by hepatic CYP1A2 into 6-sulphatoxymelatonin, which is then excreted in urine. Because CYP1A2 is not involved in inclisiran's metabolism at all, melatonin's use of that enzyme creates zero competition with inclisiran. [3]

The Glucose Tolerance Signal

This is the one pharmacodynamic flag worth discussing in full. A randomized crossover trial published in Diabetologia (N=23) found that melatonin supplementation at 10 mg per night significantly reduced insulin secretion and raised postprandial glucose compared to placebo (P<0.01). [4] A subsequent Mendelian randomization study in JAMA (N>100,000 participants) found that genetic variants associated with higher melatonin receptor 1B (MTNR1B) expression were linked to higher fasting glucose and a greater risk of type 2 diabetes. [5]

Does this matter for a patient on inclisiran? Inclisiran itself does not affect glucose or insulin signaling. However, patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) already carry elevated cardiometabolic risk. Adding an agent that modestly impairs glucose tolerance is worth noting in that context, even if the absolute magnitude is small for most people. The concern is greater at doses above 5 mg and in patients who already have impaired fasting glucose or prediabetes.

Antioxidant and Anti-inflammatory Properties

On the positive side, melatonin has shown anti-inflammatory and antioxidant effects in several small human trials and larger preclinical datasets. A meta-analysis of 22 randomized controlled trials found that melatonin supplementation significantly reduced CRP by a mean of 0.54 mg/L (95% CI: 0.32 to 0.76 mg/L). [6] Given that ASCVD patients are often managing systemic inflammation, this signal is at least directionally favorable. It does not override the glucose concern, but it is part of the full pharmacodynamic picture.

The Interaction Classification: Pharmacokinetic vs. Pharmacodynamic

Understanding whether an interaction is pharmacokinetic (PK) or pharmacodynamic (PD) changes the clinical response entirely.

PK interaction: One substance changes the plasma concentration of another by altering absorption, distribution, metabolism, or excretion. For inclisiran and melatonin, the answer is: no PK interaction exists. Their metabolic pathways are completely separate, protein-binding overlap is clinically irrelevant under realistic dosing conditions, and neither substance affects the renal clearance mechanisms relevant to the other.

PD interaction: Two substances produce additive, synergistic, or opposing effects at the target organ, even if plasma levels of neither substance change. For inclisiran and melatonin, a low-level PD concern exists around glucose homeostasis, as described above. This is not a contraindication. It is a monitoring signal.

HealthRX Interaction Classification for Inclisiran + Melatonin

| Interaction Domain | Severity | Action Required | |---|---|---| | CYP450 metabolism | None | No action | | Protein binding displacement | Negligible | No action | | LDL-C / lipid pathway | None | No action | | Glucose tolerance (doses >5 mg) | Low to moderate | Monitor fasting glucose or HbA1c if using long-term | | Sleep architecture | Potentially beneficial | No action; may improve adherence to lifestyle measures | | Bleeding / coagulation | None identified | No action |

What the Clinical Trials Show About Inclisiran's Safety Profile

ORION-9, ORION-10, and ORION-11

The Phase 3 ORION program evaluated inclisiran across three large trials. ORION-11 (N=1,617 patients with ASCVD or ASCVD-risk equivalents) showed a 49.9% placebo-adjusted mean reduction in LDL-C at 17 months. [7] Adverse events in all three trials were predominantly injection-site reactions; no hepatic toxicity, no drug-drug interactions with statins or ezetimibe, and no glucose-related adverse events were reported above placebo rates.

The ORION trials did not study melatonin co-administration. No specific data exist from randomized trials on the combined use of inclisiran and any sleep supplement. That gap is typical for siRNA therapies, which simply have not been around long enough to accumulate broad supplement-interaction trial data.

ORION-4: The Long-Term Cardiovascular Outcomes Trial

ORION-4 (N=15,000+, ongoing as of 2025) is examining hard cardiovascular endpoints including MACE (major adverse cardiovascular events) over 5 years in patients already on background statin therapy. [8] The trial population represents real-world patients, many of whom likely use OTC supplements including melatonin. Post-hoc subgroup analyses from this trial may eventually provide observational data on supplement co-use, but no results are available yet.

Inclisiran in Patients with Diabetes

A pre-specified subgroup analysis from the ORION program found that inclisiran produced consistent LDL-C reductions in patients with and without type 2 diabetes, with no significant interaction by diabetes status (P<0.001 for LDL-C reduction in both subgroups). [7] This matters because it tells us inclisiran's efficacy and safety are not meaningfully altered by the glucose dysregulation that melatonin might slightly worsen at high doses.

Practical Guidance: Using Melatonin While on Leqvio

Dose Selection for Melatonin

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline states that melatonin is most effective for circadian rhythm disorders at doses of 0.5 to 3 mg. [9] Many OTC products in the United States contain 5 to 10 mg per tablet, which is well above the physiologically relevant range for sleep promotion. Patients on Leqvio who want to use melatonin should consider starting at 0.5 to 1 mg and not exceeding 3 mg routinely. This lower dose range also minimizes the glucose tolerance signal described above.

Timing and Administration

No dose-separation window is required between inclisiran and melatonin. Inclisiran is injected twice yearly in a clinical office setting. Melatonin is taken nightly. The two substances are never in peak plasma concentration at the same time in any meaningful sense. Take melatonin 30 minutes before your target sleep time, regardless of your Leqvio injection schedule.

Monitoring Recommendations

Patients combining melatonin with inclisiran should:

• Check fasting glucose or HbA1c at their next routine visit if they plan to use melatonin nightly for more than 4 weeks.
• Report any new symptoms of hyperglycemia (excessive thirst, frequent urination, blurred vision) to their prescriber.
• Continue their scheduled lipid panel at the 3-month and 6-month post-injection marks as directed by their cardiologist or internist.
• Inform their prescriber of all supplements, including melatonin. This allows the provider to contextualize any lab changes correctly.

When to Be More Cautious

Patients who should discuss melatonin use with their physician before starting include those with:

• Prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%).
• Type 2 diabetes managed with insulin secretagogues (sulfonylureas or meglitinides), since melatonin's insulin-suppressing effect could interact with those agents separately.
• Autoimmune conditions, because high-dose melatonin (above 10 mg) may modulate immune activity.
• Concurrent use of fluvoxamine or other potent CYP1A2 inhibitors, which can raise melatonin plasma levels substantially. [3]

The concern in the last point is not about inclisiran at all. It is about melatonin's own pharmacology being amplified by another co-medication.

What Clinicians Say About siRNA Therapies and Supplement Interactions

The prescribing information for inclisiran (Leqvio, Novartis) states: "No clinically significant drug interactions have been identified for inclisiran based on in vitro studies." [1] This statement encompasses the absence of CYP-mediated and transporter-mediated interactions. It does not specifically evaluate dietary supplements, which are not required to be part of a drug's formal interaction study package.

Dr. Kausik Ray (Imperial College London), a principal investigator on the ORION-10 trial, has noted in published commentary that inclisiran's intracellular mechanism of action makes it "pharmacokinetically clean" relative to small-molecule lipid-lowering drugs, with minimal off-target systemic exposure once hepatocyte uptake is complete. [10] That assessment aligns with the clinical absence of interaction signals seen across the ORION program.

The Endocrine Society's 2023 guidelines on lipid management acknowledge that patients using PCSK9-targeting therapies frequently ask about supplement co-use, and recommend individualized counseling rather than blanket restrictions for supplements without established mechanistic interaction pathways. [11]

Comparing Inclisiran's Interaction Profile to Other Lipid-Lowering Drugs

A brief comparison helps put the melatonin question in context.

Statins vs. Inclisiran: CYP3A4 Risk

Simvastatin and lovastatin are major CYP3A4 substrates. Co-administration with CYP3A4 inhibitors (e.g., amiodarone, azithromycin, some grapefruit components) raises statin plasma levels and the risk of myopathy. Melatonin is not a CYP3A4 inhibitor, so even this route is irrelevant. Inclisiran, again, bypasses CYP3A4 entirely. The interaction risk of melatonin with inclisiran is substantially lower than the interaction risk of melatonin with many common statins.

Ezetimibe

Ezetimibe inhibits NPC1L1-mediated cholesterol absorption in the intestine. It shares no metabolic pathway with melatonin and carries no known interaction. Many patients on inclisiran are also on ezetimibe; melatonin does not complicate that regimen either.

PCSK9 Monoclonal Antibodies (evolocumab, alirocumab)

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that neutralize circulating PCSK9 protein. Like inclisiran, they are not CYP substrates and do not interact pharmacokinetically with melatonin. The same pharmacodynamic glucose-tolerance caveat at high melatonin doses applies across all PCSK9-targeting therapies. [12]

Frequently Asked Questions